Recombinant scFv

USE OF RECOMBINANT scFv ANTIBODIES TO DISRUPT FLAVONOID METABOLISM IN TRANSGENIC PLANTS... 

Horacek, J. and Skladal, P. (1998) Characterization of the interactions between immobilized parathion and the corresponding recombinant scFv antibody using a piezoelectric biosensor. Food Agric. Immunol. 10, 363-374... 

Liu H, Ding Y L, Han W, Liu M Y, et al. (2004). Recombinant scFv antibodies against E protein and N protein of severe acute respiratory syndrome virus. Acta Biochim. Biophys. Sin. 36 541-547. 

One marketed antibody therapeutic, ReoPro, is in Fab rather than IgG format (Table 1). In addition, one F(ab )2 fragment derived by limited proteolysis of murine MAb is currently in phase III therapy trials (Table 2) (1,3). Thus far, recombinant scFv (113) and F(ab )2 (114) fragments have been tested in the clinic and more recently PEGylated versions of Fab and F(ab )2 fragments (see below). 

In mice with human breast carcinoma xenografts, a humanized IgG anti-HER-2 MAb eradicated well-established tumours [58]. In addition, a humanized version of an IgG anti-CD33 MAb (HuM 195) mediated ADCC in vitro [59] and had an 8.6-fold higher avidity than the parent murine Mab. Recombinant antibody fragments may have valnable properties as discnssed above, bnt their biophysical behavionr, prodnction yield and low thermostability leaves mnch to be desired and thereby limits their nsefnlness for in-vivo applications so far [60]. One possibility to improve these characteristics of scFv fragments with snboptimal stability and/or folding yield, is the grafting of their CDRs onto the framework of a different, more stable scFv [61,62]. 

Teunissen, S.W.M., Stassen, M.H.W., Pruijn, G.J.M., van Venrooij, W.J., Hoet, R.M.A. (1998). Characterization of an anti-RNA recombinant autoantibody fragment (scFv) isolated from a phage display library and detailed analysis of its binding site on U1 snRNA. RNA, 4, 1124-1133. 

---